The one-shot retinal dystrophy treatment ‘Luxturna’ has entered its last stage to reimbrursement in Korea.

According to industry sources, Novartis Korea recently entered drug pricing negotiations for its Inherited Retinal Dystrophy (IRD) treatment Luxturna (voretigene neparvovec) with the National Health Insurance Service.

Luxturna passed the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee review on September 7th. The company had applied for reimbursement of its drug in September 2021, but no progress had been made at the time. In March, Luxturna failed to pass the Drug Reimbursement Evaluation Committee review and set reimbursement standards